Laboratorios Farmaceuticos Rovi (ROVIN) Stock Statistics & Valuation Metrics

Laboratorios Farmaceuticos Rovi has a market cap or net worth of $59.14B. The enterprise value is $4.16K.

Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.

Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 16.52%.

The current PE Ratio of Laboratorios Farmaceuticos Rovi is 27.3. Laboratorios Farmaceuticos Rovi’s PEG ratio is 7.71.

In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 743.48M and earned 140.44M in profits. Earnings per share was 2.75.

In the last 12 months, operating cash flow was 252.69M and capital expenditures -75.91M, giving a free cash flow of 176.78M billion.

Laboratorios Farmaceuticos Rovi pays an annual dividend of ―, resulting in a dividend yield of ―

Laboratorios Farmaceuticos Rovi upcoming earnings date is Nov 5, 2026, TBA (Confirmed).

Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 0.00%

In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 42.90M in taxes.

Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 16.07, with an EV/FCF ratio of 27.23.

Laboratorios Farmaceuticos Rovi has $128.07M in cash and marketable securities with $0.00 in debt, giving a net cash position of $128.07M billion.

Gross margin is 64.02%, with operating margin of 23.29%, and net profit margin of 18.89%.

The average price target for Laboratorios Farmaceuticos Rovi is $1,467.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy